Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Glycomed Inc. deal

Sankyo will invest $1.5 million in the Alameda, Calif., company and pay a $1 million licensing fee. GLYC, which

Read the full 194 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE